CAJ | 학술논문

目的：比较替吉奥( S-1)+奥沙利铂和FOLFOX6方案辅助化疗在可切除II/芋期胃癌围术期患者中的疗效及药物不良反应。方法回顾性分析可切除II/芋期胃癌围术期辅助S-1+奥沙利铂方案( A组)和FOLFOX6方案( B组)化疗的患者40例,比较两种辅助化疗方案的疗效、术后辅助化疗无疾病进展生存期、 KPS评分及药物不良反应。结果两组的客观缓解率( objective response rate, ORR)差异无统计学意义(字2=2.849, P>0.05)。A组和B组的无疾病进展生存期分别为316.000天和341.000天,差异有统计学意义(字2=5.566, P=0.018)。 B组KPS评分明显低于A组( t=2.122, P=0.040)； B组的恶心呕吐发生率高于A组(字2=4.800, P=0.028),两组患者的Ⅲ~Ⅳ级不良反应主要为血液系统毒性。结论可切除II/芋期胃癌围术期辅助FOLFOX6方案化疗的中期疗效优于S-1+奥沙利铂方案,但药物不良反应发生率高, KPS评分低。
목적：비교체길오( S-1)+오사리박화FOLFOX6방안보조화료재가절제II/우기위암위술기환자중적료효급약물불량반응。방법회고성분석가절제II/우기위암위술기보조S-1+오사리박방안( A조)화FOLFOX6방안( B조)화료적환자40례,비교량충보조화료방안적료효、술후보조화료무질병진전생존기、 KPS평분급약물불량반응。결과량조적객관완해솔( objective response rate, ORR)차이무통계학의의(자2=2.849, P>0.05)。A조화B조적무질병진전생존기분별위316.000천화341.000천,차이유통계학의의(자2=5.566, P=0.018)。 B조KPS평분명현저우A조( t=2.122, P=0.040)； B조적악심구토발생솔고우A조(자2=4.800, P=0.028),량조환자적Ⅲ~Ⅳ급불량반응주요위혈액계통독성。결론가절제II/우기위암위술기보조FOLFOX6방안화료적중기료효우우S-1+오사리박방안,단약물불량반응발생솔고, KPS평분저。
Objective To evaluate the efficacy and toxicity of S-1 plus oxaliplatin versus FOLFOX6 as perioperative chemotherapy for resectable gastric cancer of stageII/I. Method 40 patients with resectable gastric cancer of stageII/Ⅲ administered with S-1 plus oxaliplatin ( group A) or FOLFOX6 ( group B) as perioperative chemotherapy were analyzed retrospectively to compare the efficacy, progression-free survival ( PFS) , KPS score and the toxicity of the two regimens. Result The difference was significant in respect of ORR (x2=2.849, P>0.05); And the median time to progression-free survival was 316 days vs 341 days (x2=5.566, P=0.018) for group A and B;and the KPS score of group B was ob-viously lower than that of group A ( t=2.122, P=0.040) . As for the adverse reactions, nausea and vomiting were more common in group B than in group A (x2=4.800, P=0.028);and the most common toxic reaction was toxicity of hemato-logical system in both groups. Conclusion The efficacy of FOLFOX6 is better than S-1 plus oxaliplatin, while the inci-dence of grade Ⅲ-Ⅳ toxicity is higher, with relatively lower KPS score.